[Action of the anti-inflammatory agent Lonazolac on experimentally-induced acute inflammation of human skin].
Using two experimental models of acute dermatitis in man, Lonazolac proved to possess dose-dependent anti-inflammatory effects. No untoward side effects were seen even at the higher doses of the drug. The results are consistent with animal studies: In its effect on the acute experimental dermatitis, Lonazolac resembles indomethacin more closely than oxyphenbutazone. It is superior to the comparable anti-inflammatory drugs in its effect on the inflammatory erythema of the skin; in its effect on the inflammatory edema of the skin, it stands between oxyphenbutazone and indomethacin.
D000085:Acetates / Q000627:therapeutic use; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy*; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010113:Oxyphenbutazone / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use*
D000085:Acetates; D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; C017472:lonazolac; D010113:Oxyphenbutazone; D007213:Indomethacin
Die Wirkung des Antiphlogistikum Lonazolac auf experimentell erzeugte akute Enlzündungen an der menschlichen Haut.